Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
68.65 EUR | +0.88% | +0.96% | +101.91% |
Business Summary
Number of employees: 464
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Cancer Medicines
100.0
%
| 278 | 100.0 % | 238 | 100.0 % | -14.37% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
88.8
%
| 0 | 0.0 % | 211 | 88.8 % | - |
Europe (excluding Germany)
11.2
%
| - | - | 27 | 11.2 % | - |
Asia
0.0
%
| - | - | 0 | 0.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 19-08-31 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 23-08-06 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-31 |
Tim Demuth
CTO | Chief Tech/Sci/R&D Officer | 50 | 22-09-30 |
Julia Neugebauer
IRC | Investor Relations Contact | - | 06-08-31 |
Daniel Palmacci
PRN | Corporate Officer/Principal | - | 20-06-30 |
Ann Merchant
PRN | Corporate Officer/Principal | 59 | 17-12-31 |
Ralf Ostendorp
PRN | Corporate Officer/Principal | - | 98-12-31 |
Corporate Officer/Principal | - | 94-04-30 | |
Klaus de Wall
AUD | Comptroller/Controller/Auditor | - | 05-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 18-05-16 |
Director/Board Member | 67 | 18-05-16 | |
Marc Cluzel
CHM | Chairman | 69 | 12-05-30 |
Andrew Cheng
BRD | Director/Board Member | 57 | 22-05-17 |
Krisja Vermeylen
BRD | Director/Board Member | 62 | 16-12-31 |
Sharon Curran
BRD | Director/Board Member | 56 | 19-05-21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 37,716,423 | 6,497,716 ( 17.23 %) | 53,685 ( 0.1423 %) | 17.23 % |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+101.91% | 2.8B | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- MOR Stock
- Company MorphoSys AG